To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00761540
Recruitment Status : Completed
First Posted : September 29, 2008
Last Update Posted : January 26, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S